- About UT Dallas
- Campus Life
UT Dallas’ Enhanced Rehab for Stroke Doubles Movement Recovery
Sept. 27, 2018
Targeted plasticity via vagus nerve stimulation could be used to restore motor functions lost due to stroke or brain injury by using the brain’s natural ability to reorganize. If you don’t see the video, watch it on Vimeo.
A novel therapy technique invented by researchers at The University of Texas at Dallas has been shown in a pilot study to double the rate of upper limb recovery in stroke patients, a leap forward in treating the nearly 800,000 Americans who suffer strokes each year.
The results of the study, funded by UT Dallas spinoff company MicroTransponder of Austin, Texas, were published Sept. 27 in the journal Stroke.
The findings indicate that targeted plasticity therapy — which involves stimulation of the vagus nerve paired with traditional motor-skill rehabilitation — is not only safe, but also twice as effective as rehab alone.
Dr. Jane Wigginton, the chief medical officer at UT Dallas’ Texas Biomedical Device Center (TxBDC) and an associate professor of emergency medicine at UT Southwestern Medical Center, led the Dallas site of the clinical trial, which involved 17 people across the country who had suffered a stroke.
Dr. Jane Wigginton
“Stroke is too common and too debilitating for us to tolerate the status quo,” said Wigginton, who is also the chief medical advisor at the Center for BrainHealth at UT Dallas. “Patients need a real solution so they can get back to fully living their lives.”
Dr. Michael Kilgard, associate director and chief science officer of the TxBDC, invented targeted plasticity therapy (TPT). Kilgard, who is also the Margaret Fonde Jonsson Professor in the School of Behavioral and Brain Sciences (BBS), said the study results further validate the theories that he and his colleagues based their TPT work on beginning in 2009.
“We set out to design an approach that could transform long-term care and restore quality of life to patients for whom that has thus far been impossible,” said Kilgard, who was not involved in the clinical trial. “These results show our method has immense potential. We’re excited about what this could mean for millions of stroke patients worldwide.”
Researchers affiliated with the TxBDC and BBS developed the therapy technique, which pairs physical movements with precisely timed vagus nerve stimulation (VNS) — electrical stimulus of the nerve via a device implanted on the nerve in the neck.
The vagus nerve controls the parasympathetic nervous system, overseeing many unconscious functions such as circulation and digestion. Stimulating the nerve initiates neural plasticity — reorganization of the brain’s circuitry. The idea behind TPT is that synchronizing VNS with movement accelerates plasticity in a damaged brain, and with it, recovery.
A stroke occurs when blood flow to the brain is interrupted because of a blockage or a ruptured blood vessel. Limb mobility can be affected when nerve cells are damaged. Such forms of brain trauma are often treated with rehabilitation that includes repeated movement of the affected limb in an effort to regain motor skills. The approach is thought to work by helping the brain reorganize.
“We set out to design an approach that could transform long-term care and restore quality of life to patients for whom that has thus far been impossible. These results show our method has immense potential. We’re excited about what this could mean for millions of stroke patients worldwide.”
Several studies of Kilgard’s technique in animal models have previously demonstrated that it is effective in recovering limb function after stroke. A small clinical trial in Europe also provided encouraging data for its potential use in humans.
In 2009, UT Dallas licensed its VNS technique as a stroke and tinnitus treatment to MicroTransponder, which sponsored the new double-blind, placebo-controlled study. Neither the researchers nor the study subjects knew who was getting VNS stimulation and who was not.
Each study subject was a stroke patient whose stroke occurred between four months and five years prior to selection. After they had a VNS device implanted, the subjects received six weeks of in-clinic rehab followed by a home exercise program. About half were treated with active VNS while the rest received control VNS. All were assessed one, 30 and 90 days after therapy with a widely used, stroke-specific measure of performance impairment.
In addition to showing that the technique is safe, the researchers found that subjects receiving active VNS scored more than twice as high as control subjects at the 30- and 90-day intervals, opening the way for larger, more extensive clinical trials, Kilgard said. One such trial is in the recruitment phase and includes a study site in Dallas.
Other institutions involved in the study included The University of Texas Health Science Center at Houston; the University of Minnesota; the University of California, Irvine; the University of Glasgow; and Massachusetts General Hospital.
MicroTransponder had no responsibility for the analysis and interpretation of study data and had no responsibility for writing of the trial report or in the decision to submit the paper for publication. Kilgard is a shareholder and consultant for MicroTransponder Inc.